FRANKFURT (Reuters) -Bayer said on Monday it would shrink the Crop Science division’s production, research and development activities in Germany, citing pressure from cheap generic products, stricter regulation and export barriers.
“These steps are urgently needed to counteract the significant overcapacity and a hopeless price competition with generics manufacturers from Asia,” the company said in a statement.
It also cited “increasing regulatory restrictions and national export barriers” in a bid to focus on “strategic, innovative technologies.”
Among the cutbacks, Bayer seeks to end its activities in Frankfurt, where it produces and develops herbicides with about 500 staff, after the end of 2028.
Activities there would be sold or relocated, Bayer said.
At the Dormagen site, production of various generic active ingredients will be gradually stopped by the end of 2028, impacting about 200 positions of the nearly 1,200 employees.
“We want to find viable solutions for our colleagues together with employee representatives,” Bayer added.
(Reporting by Ludwig Burger, editing by Thomas Seythal)
